Disease index

obesity

Metabolic · 2023–2023

1decision
1medicine
1carried consumer input
104individual submissions

Every decision

MedicineMeetingOutcomeConsumer input
semaglutide Treatment of severe obesity (BMI ≥40 kg/m² or ≥37 kg/m² for Asian or Aboriginal/Torres Strait Islander patients) with at least two weight-related comorbidities… Nov 2023 Not recommended 104 individuals National Aboriginal Community Controlled Health Organisation · Liver Foundation · Arthritis Australia · Weight Issues Network

Who spoke

National Aboriginal Community Controlled Health Organisation · Liver Foundation · Arthritis Australia · Weight Issues Network

What the PBS pays

$260M in government benefit over 2024–25, across 2,176,978 services.

This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.

MedicineGovernment benefit
semaglutide $260.5M

Appraised elsewhere

NICE, in England and Wales, has appraised 2 technologies for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.

TechnologyAppraisalOutcomeDate
tirzepatideTirzepatide for managing overweight and obesity TA1026 recommended restricted 2024-12
liraglutideLiraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal) TA749 terminated 2021-12

Registered, not subsidised

Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.

MedicineOn the ARTG sinceRegistrations
phentermineALENAMI phentermine (as hydrochloride) 15 mg sustained release capsule 1991 54
bupropion + naltrexoneCONTRAVE 8/90 naltrexone hydrochloride 8 mg and bupropion hydrochlori 2018 1

The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.

Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.